@article{3022374,
    title = "Editorial: The new trial EMPAREG-outcomes in type 2 diabetes: “and death shall have no dominion”?",
    author = "Papanas, N. and Tsioufis, C. and Maltezos, E.S.",
    journal = "Current Vascular Pharmacology",
    year = "2016",
    volume = "14",
    number = "4",
    pages = "316-318",
    publisher = "Bentham Science Publishers B.V.",
    issn = "1570-1611",
    doi = "10.2174/1570161114999160229142200",
    keywords = "alogliptin;  empagliflozin;  glucagon;  hemoglobin A1c;  high density lipoprotein cholesterol;  insulin glargine;  lixisenatide;  low density lipoprotein cholesterol;  saxagliptin;  sitagliptin;  antidiabetic agent;  benzhydryl derivative;  glucoside, body weight;  cardiovascular mortality;  cerebrovascular accident;  clinical trial (topic);  Editorial;  glycemic control;  heart failure;  heart infarction;  hospitalization;  human;  non insulin dependent diabetes mellitus;  outcome assessment;  systolic blood pressure;  transient ischemic attack;  waist circumference;  cardiovascular disease;  complication;  mortality;  non insulin dependent diabetes mellitus, Benzhydryl Compounds;  Cardiovascular Diseases;  Diabetes Mellitus, Type 2;  Glucosides;  Humans;  Hypoglycemic Agents"
}